Progress in treatment of ANCA-associated vasculitis.

Arthritis Research & Therapy
Rona M SmithDavid Jayne

Abstract

Autoantibodies to neutrophil cytoplasmic antigen-associated vasculitis (AAV) is characterised by inflammation of blood vessels. The introduction of immunosuppressive therapy with glucocorticoids and cyclophosphamide transformed AAV from a fatal condition to a largely treatable condition. Over the past 30 years, considerable progress has been made refining immunosuppressive regimens with a focus on minimising toxicity. There is, however, a high unmet need in the treatment of AAV. A proportion of patients are refractory to current therapies; 50% experience a relapse within 5 years and treatment toxicity contributes to mortality and chronic disability. As knowledge of the pathogenesis of vasculitis grows, it is mirrored by the availability of biological agents, which herald a revolution in the treatment of vasculitis. Lymphocyte-targeted and cytokine-targeted agents have been evaluated for the treatment of AAV and are entering the routine therapeutic arena with the potential to improve patient outcomes. As rare diseases, treatment advances in vasculitis depend on international collaborative research networks both to establish an evidence base for newer agents and to develop recommendations for patient management.

References

Mar 15, 1992·Annals of Internal Medicine·G S HoffmanA S Fauci
Feb 1, 1994·Arthritis and Rheumatism·J C JennetteC G Kallenberg
Mar 1, 1996·Annals of Internal Medicine·C Talar-WilliamsM C Sneller
Aug 27, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·M HaubitzR Brunkhorst
Jun 30, 2000·QJM : Monthly Journal of the Association of Physicians·D R JayneC M Lockwood
Sep 27, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·K de GrootUNKNOWN EUVAS (European vasculitis study group)
Jan 5, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Hugh GallagherDavid R W Jayne
Oct 9, 2002·The Journal of Clinical Investigation·Hong XiaoJ Charles Jennette
Jul 4, 2003·The New England Journal of Medicine·David JayneUNKNOWN European Vasculitis Study Group
Jul 11, 2003·The New England Journal of Medicine·Cornelia M Weyand, Jörg J Goronzy
Dec 5, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Philip J KlemmerRonald J Falk
Jan 7, 2004·The Journal of Experimental Medicine·Brian P O'ConnorRandolph J Noelle
Feb 24, 2004·Journal of the American Society of Nephrology : JASN·Anthony BoothDavid Jayne
Apr 17, 2004·Kidney International·Wilhelm H SchmittUNKNOWN European Vasculitis Study Group
Sep 9, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Frederick W K TamCharles D Pusey
Jan 28, 2005·The New England Journal of Medicine·UNKNOWN Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
Jul 6, 2005·Clinical and Experimental Immunology·P Lamprecht
Jul 28, 2005·Current Rheumatology Reports·Suzanne E LaneDavid G I Scott
Aug 30, 2005·Annals of the New York Academy of Sciences·Karina de LeeuwMarc Bijl
Oct 26, 2005·Journal of Autoimmunity·Markus KrumbholzEdgar Meinl
Nov 25, 2005·Journal of the American Society of Nephrology : JASN·Mark A LittleCharles D Pusey
Apr 29, 2006·Arthritis and Rheumatism·John H StoneUNKNOWN Wegener's Granulomatosis Etanercept Trial Research Group
Dec 5, 2006·Current Opinion in Rheumatology·Christian PagnouxLoïc Guillevin
May 24, 2007·Rheumatology·C MetzlerUNKNOWN German Network of Rheumatic Diseases
Jun 1, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Polly R PineErnest Brahn
Jun 22, 2007·Journal of the American Society of Nephrology : JASN·David R W JayneUNKNOWN European Vasculitis Study Group
Jun 29, 2007·Journal of the American Society of Nephrology : JASN·Robert A F de Lind van WijngaardenUNKNOWN EUVAS
Sep 7, 2007·Rheumatology·C LapraikUNKNOWN BSR and BHPR Standards, Guidelines and Audit Working Group

❮ Previous
Next ❯

Citations

Apr 23, 2013·Annals of the Rheumatic Diseases·Arnaud MilletLuc Mouthon
Dec 18, 2012·Arthritis Research & Therapy·Ilka KnütterElena Csernok
Jan 28, 2014·Journal of Autoimmunity·Cees G M Kallenberg
Jul 3, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Cees G M KallenbergPeter Heeringa
Mar 13, 2013·La Presse médicale·Luc Mouthon
May 7, 2013·Neurologic Clinics·Michael P CollinsJohn T Kissel
Oct 15, 2014·Clinical Reviews in Allergy & Immunology·Maria Sole ChimentiRoberto Perricone
May 21, 2015·Autoimmunity Reviews·Antonio GrecoMarco de Vincentiis
May 28, 2014·Clinical Rheumatology·Marcelo Fernandez CasaresMarcelo Zamboni
May 30, 2015·La Presse médicale·Rona M Smith
Dec 18, 2013·Lancet Neurology·Kelly Graham GwathmeyP James Bonham Dyck
Jun 19, 2016·QJM : Monthly Journal of the Association of Physicians·B A McNicholasM D Griffin
Sep 28, 2016·International Urology and Nephrology·Ágnes HarisKálmán Polner
Mar 26, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Matthias SchaierClaudia Sommerer
Mar 15, 2014·Clinical Journal of the American Society of Nephrology : CJASN·William F PendergraftJohn L Niles
May 28, 2019·Current Rheumatology Reports·Nkechinyere Emejuaiwe
Mar 24, 2021·Rheumatology·Leo SegelmarkAladdin J Mohammad

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Clinical Trials Mentioned

NCT00987389
NCT00468208

Software Mentioned

RITUXVAS
NORAM
RAVE
SOLUTION

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Rachel B JonesEuropean Vasculitis Study Group
The New England Journal of Medicine
John H StoneRAVE-ITN Research Group
The New England Journal of Medicine
Paul A LyonsKenneth G C Smith
© 2021 Meta ULC. All rights reserved